c-Src (A16) Antibody-Delta Biolabs

Product Info
Background	The Src gene family is represented by at least eight different protein tyrosine kinases belonging to the non-receptor tyrosine kinases (1,2). These protein tyrosine kinases are important regulators of many cellular processes, including cytoskeletal organization, cell-cell contact, DNA synthesis, and cellular proliferation (1-3). Members of this group of proteins include c-Src, c-Yes, Fyn, Lck, Lyn, Hck, Blk and c-Fgr. The proto-oncogene c-Src is the prototype member of this gene family and is expressed in a broad range of tissues and cells (4,5). Elevated c-Src tyrosine kinase activity has been found in many types of human cancers, most notably in breast carcinomas (6,7). The activity of c-Src in these human cancers has been attributed to increases c-Src expression, elevated c-Src specific activity and activating mutations in c-Src (6,7).
*Product Citations*	1.)Ardizzone TD, Zhan X, Ander BP, Sharp FR. 2007, SRC kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage. Stroke. 2007 May;38(5):1621-5.
Origin	c-Src (A16) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the amino terminus of human c-Src p60.
Product Details	Each vial contains 200 �g/ml of affinity purified rabbit IgG, c-Src (A16) DB023, in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
Competition Studies	A blocking peptide is also available, DB023P, for use in competition studies. Each vial contains 0.100 mg of peptide in 0.5 ml PBS with 0.1% sodium azide and 100 mg BSA.
Form	200 �g/ml rabbit polyclonal IgG in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
Immunogen	Synthetic peptide mapping to the amino terminus of human c-Src p60.
Specificity	c-Src (A16) DB023 reacts with c-Src p60 of mouse, rat and human origin
Use	Western blotting and immunoprecipitation. Western blotting starting dilution: 1:200.
Storage	Store this product at 4� C, do not freeze. The product is stable for one year from the date of shipment.
References	1. Oda H, Kumar S, Howley PM. 1999. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci USA 96(17):9557-9562. 2. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. 2000. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interaction in breast cancer. Breast Cancer Res 2(3):203-210. 3. Ingraham CA, Cox ME, Ward DC, Fults DW, Maness PF. 1989. c-Src and other proto-oncogenes implicated in neuronal differentiation. Mol Chem Neuropathol 10(1):1-14. 4. Wiestler OD, Walter G. 1988. Developmental expression of two forms of pp60c-src in mouse brain. Mol Cell Biol 8(1):502-504. 5. Yang XM, Martinez R, Le Beau J, Wiestler O, Walter G. Evolutionary expression of the neuronal form of the src protein. Proc Natl Acad Sci USA 86(12):4751-4755. 6. Bjorge JD, Pang A, Fujita DJ. 2000. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 275(52):41439-41446. 7. Hung W, Elliot B. 2001. Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells. J Biol Chem 276(15):12395-12403.